1)Committee on Practice Bulletins-Obstetrics:ACOG Practice Bullentin No. 203;Chronic hypertension in pregnancy. Obstet Gynecol 133:e26-e50, 2019
2)National Institute for Health and Care Excellence:Hypertension in pregnancy;Diagnosis and management, 2010 https://www.nice.org.uk/guidance/cg107(2019年6月閲覧)
3)Abalos E, et al:Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 10:CD002252, 2018
4)Podymow T, August P:New evidence in the management of chronic hypertension in pregnancy. Semin Nephrol 37:398-403, 2017
5)Kamiya CA, et al:Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. —Results from the Japanese Nationwide survey of peripartum cardiomyopathy—. Circ J 75:1975-1981, 2011
6)Isogai T, Kamiya CA:Worldwide incidence of peripartum cardiomyopathy and overall maternal motality. Int Heart J 60:503-511, 2019
7)Honigberg MC, Givertz MM:Peripartum cardiomyopathy. BMJ 364:k5287, 2019
8)Reddy S, Jim B:Hypertension and pregnancy;Management and future risks. Adv Chronic Kidney Dis 26:137-145, 2019
9)Mito A, et al:Hypertensive disorders of pregnancy;A strong risk factor for subsequent hypertension 5 years after delivery. Hypertens Res 41:141-146, 2018
10)伊藤真也,村島温子(編):薬物治療コンサルテーション—妊娠と授乳(改訂第2版),pp 316-322,南山堂,2014
11)日本産婦人科学会,日本産婦人科医会(編):産婦人科診療ガイドライン—産科編2017, pp 79-81,日本産科婦人科学会,2017
12)Bateman BT, et al:Late pregancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 138, 2016
13)Nayak AS, Nachane HB:Risk analysis of suicidal ideations and postpartum depression with antenatal alpha methyldopa use. Asian J Psychiatr 38:42-44, 2018